Evidence Hub

Network pharmacology-guided self-assembling quercetin hydrogel from Astragalus membranaceous accelerates diabetic wound healing

Liu M, Zhou H, Wang J, Wang Y, Cai C, Han C, Dong L, Wang X

Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026

Abstract

BACKGROUND: Delayed diabetic wound healing remains a significant clinical challenge. Astragalus membranaceus, a traditional Chinese herb, is widely used for the topical treatment of diabetic wounds. However, its complex composition has hampered the identification of its main active components and precise mechanisms of action.

PURPOSE: This study aimed to identify the main active component of A. membranaceous responsible for diabetic wound healing and to develop an advanced nanocomposite delivery system to enhance its therapeutic efficacy.

METHODS: The main active component and its core therapeutic targets were screened using network pharmacology and validated by molecular docking. To address the inherent limitations of the identified component, quercetin-loaded chitosan nanoparticles (QNPs) were fabricated via self-assembly and subsequently incorporated into a gelatin methacryloyl (GelMA) hydrogel to form QNPs@GelMA. The therapeutic effects of QNPs@GelMA were systematically evaluated in vitro and in vivo using a range of techniques including ROS test, histopathological staining, immunofluorescence, and TUNEL staining.

RESULTS: Network pharmacology and molecular docking identified quercetin as the main active component of A. membranaceous, with core targets involving JUN, IL-6, IL-1β, and TP53. The constructed QNPs@GelMA hydrogel facilitated sustained release of quercetin at the wound site. In cellular and animal experiments, QNPs@GelMA significantly enhanced diabetic wound…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free